- Home
- AMTB vs SYRE Comparison
AMTB vs SYRE Comparison
Compare AMTB & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMTB
- SYRE
- Stock Information
- Founded
- AMTB 1979
- SYRE 2013
- Country
- AMTB United States
- SYRE United States
- Employees
- AMTB N/A
- SYRE N/A
- Industry
- AMTB Major Banks
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- AMTB Finance
- SYRE Health Care
- Exchange
- AMTB Nasdaq
- SYRE Nasdaq
- Market Cap
- AMTB 756.7M
- SYRE 841.4M
- IPO Year
- AMTB N/A
- SYRE 2016
- Fundamental
- Price
- AMTB $16.67
- SYRE $15.01
- Analyst Decision
- AMTB Hold
- SYRE Buy
- Analyst Count
- AMTB 5
- SYRE 6
- Target Price
- AMTB $24.33
- SYRE $55.00
- AVG Volume (30 Days)
- AMTB 190.1K
- SYRE 521.8K
- Earning Date
- AMTB 07-23-2025
- SYRE 08-06-2025
- Dividend Yield
- AMTB 2.16%
- SYRE N/A
- EPS Growth
- AMTB N/A
- SYRE N/A
- EPS
- AMTB N/A
- SYRE N/A
- Revenue
- AMTB $280,716,000.00
- SYRE N/A
- Revenue This Year
- AMTB $57.57
- SYRE N/A
- Revenue Next Year
- AMTB $8.91
- SYRE N/A
- P/E Ratio
- AMTB N/A
- SYRE N/A
- Revenue Growth
- AMTB N/A
- SYRE N/A
- 52 Week Low
- AMTB $16.21
- SYRE $10.91
- 52 Week High
- AMTB $27.00
- SYRE $40.26
- Technical
- Relative Strength Index (RSI)
- AMTB 38.90
- SYRE 42.53
- Support Level
- AMTB $16.50
- SYRE $13.93
- Resistance Level
- AMTB $18.35
- SYRE $18.01
- Average True Range (ATR)
- AMTB 0.42
- SYRE 1.14
- MACD
- AMTB -0.07
- SYRE -0.26
- Stochastic Oscillator
- AMTB 9.19
- SYRE 20.49
About AMTB Amerant Bancorp Inc.
Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.